Source: Science Direct

René Lima-Morales, Pablo Méndez-Hernández, Yvonne N. Flores, Patricia Osorno-Romero, Elizabeth Cuecuecha-Rugerio, Adrián Nava-Zamora, Diego Rolando Hernández-Galdamez, Daniela Karola Romo-Dueñas, Jorge Salmerón

Highlights

•TNR4 is a multidrug therapy (Ivermectin, Azithromycin, Montelukast and ASA) for COVID-19 cases.

•TNR4 increased the likelihood of recovery 3.4 times in ambulatory COVID-19 cases.

•The multidrug therapy TNR4 reduced the risk of hospitalization by 75%.

•The multidrug therapy TNR4 reduced the risk of death by 81%.

Abstract

Objective

There is an urgent need for effective treatments to prevent or attenuate lung and systemic inflammation, endotheliitis, and thrombosis related to COVID-19. The aim of this study was to assess the effectiveness of a multidrug-therapy consisting of Ivermectin, Azithromycin, Montelukast and Acetylsalicylic Acid (“TNR4” therapy) to prevent hospitalization and death among ambulatory COVID-19 cases in Tlaxcala, Mexico.

Design and Methods

A comparative effectiveness study was performed among 768 confirmed SARS-CoV-2 cases aged 18 to 80 years, who received ambulatory care at the Ministry of Health of Tlaxcala. A total of 481 cases received the TNR4 therapy, while 287 received another treatment (comparison group). All participants received home visits and/or phone calls for clinical evaluation during the 14 days after enrollment.

Results

Nearly 85% of cases who received the TNR4 recovered within 14 days compared to 59% in the comparison group. Likelihood of recovery within 14 days was 3.4 times greater among the TNR4 group than in the comparison group. Patients treated with TNR4 had a 75% and 81% lower risk of being hospitalized or death, respectively, than the comparison group.

Conclusions

TNR4 therapy improved recovery and prevented risk of hospitalization and death among ambulatory COVID-19 cases.

Download the full text PDF here: https://video.palmerfoundation.com.au/media/2021/02/20210210-Effectiveness-of-Multidrug-therapy-inc-Ivermectin-Mexico.pdf







Related: Melbourne doctors urge officials to consider hydroxychloroquine, ivermectin in fight against COVID-19

Peru: Regional Governor of Piura promotes ivermectin consumption

HCQ and Ivermectin included in multifaceted highly targeted sequential multidrug treatment of early ambulatory high-risk COVID-19

Hydroxychloroquine and Ivermectin: The medical establishment’s war on COVID therapeutics

Sahpra announces controlled compassionate access to Ivermectin: South Africa

HCQ and Ivermectin included in multifaceted highly targeted sequential multidrug treatment of early ambulatory high-risk COVID-19

Multifaceted highly targeted sequential multidrug treatment of early ambulatory high-risk COVID-19 infection includes HCQ & Ivermectin

Ivermectin for Covid-19: Database of all Ivermectin COVID-19 studies – 35 trials and growing

Share on facebook
Share on twitter
Share on whatsapp
On Trend

Latest Stories

Facebook Suspends Craig Kelly For Posts Citing Medical Professionals

“The effect of censoring debate on these early treatments could have possibly been responsible for the death of hundreds of thousands of people.
So, where we should have been having more open debate and more free debate, shutting down debate is likely to have killed people. Not just one or two people, but probably hundreds of thousands. This is why throughout the last 250 years people have said free speech is so important. This is why people have said, ‘I may not agree with what you say but I’ll fight to my death your right to say it.’”

Read More »